CRYOPORT, INC. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Mr. Shelton; PEO total compensation $2.38M; PEO compensation actually paid $2.65M; Other NEO average total compensation $1.06M.
- 2024-12-31: PEO Mr. Shelton; PEO total compensation $1.87M; PEO compensation actually paid $962.52K; Other NEO average total compensation $979.44K.
- 2023-12-31: PEO Mr. Shelton; PEO total compensation $2.24M; PEO compensation actually paid $1.50M; Other NEO average total compensation $1.04M.
- 2022-12-31: PEO Mr. Shelton; PEO total compensation $2.49M; PEO compensation actually paid -$7.38M; Other NEO average total compensation $1.11M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Mr. Shelton | $2.38M | $2.65M | $1.06M | $1.15M | $21.88 | $105.18 | $78.30M | Adjusted EBITDA -$5.78M | 2026-04-22 |
| 2024-12-31 | Mr. Shelton | $1.87M | $962.52K | $979.44K | $694.81K | $17.73 | $101.11 | -$114.76M | -$15.12M | 2026-04-22 |
| 2023-12-31 | Mr. Shelton | $2.24M | $1.50M | $1.04M | $788.43K | $35.30 | $104.28 | -$99.59M | -$8.30M | 2026-04-22 |
| 2022-12-31 | Mr. Shelton | $2.49M | -$7.38M | $1.11M | -$1.72M | $39.54 | $106.56 | -$37.33M | $13.70M | 2026-04-22 |
| 2021-12-31 | Mr. Shelton | $5.13M | $9.64M | $1.92M | $3.12M | $134.85 | $140.28 | -$275.53M | $21.24M | 2026-04-22 |
| 2024-12-31 | Mr. Shelton | $1.87M | $962.52K | $979.44K | $694.81K | $47.27 | $137.15 | -$114.76M | Adjusted EBITDA -$15.12M | 2025-04-25 |
| 2023-12-31 | Mr. Shelton | $2.24M | $1.50M | $1.04M | $788.43K | $94.11 | $141.45 | -$99.59M | -$8.30M | 2025-04-25 |
| 2022-12-31 | Mr. Shelton | $2.49M | -$7.38M | $1.11M | -$1.72M | $105.41 | $144.55 | -$37.33M | $13.70M | 2025-04-25 |
| 2021-12-31 | Mr. Shelton | $5.13M | $9.64M | $1.92M | $3.12M | $359.48 | $190.28 | -$275.53M | $21.24M | 2025-04-25 |
| 2020-12-31 | Mr. Shelton | $5.48M | $15.79M | $1.81M | $4.50M | $266.59 | $135.64 | -$32.69M | -$390.00K | 2025-04-25 |
| 2023-12-31 | Mr. Shelton | $2.24M | $1.50M | $1.04M | $788.43K | $94.11 | $141.45 | -$99.59M | Adjusted EBITDA -$8.30M | 2024-04-03 |
| 2022-12-31 | Mr. Shelton | $2.49M | -$7.38M | $1.11M | -$1.72M | $105.41 | $144.55 | -$37.33M | $13.70M | 2024-04-03 |
| 2021-12-31 | Mr. Shelton | $5.13M | $9.64M | $1.92M | $3.12M | $359.48 | $190.28 | -$275.53M | $21.24M | 2024-04-03 |
| 2020-12-31 | Mr. Shelton | $5.48M | $15.79M | $1.81M | $4.50M | $266.59 | $135.64 | -$32.69M | -$390.00K | 2024-04-03 |
| 2022-12-31 | Mr. Shelton | $2.49M | -$7.38M | $1.11M | -$1.72M | $105.41 | $144.55 | -$37.33M | Adjusted EBITDA $13.70M | 2023-03-31 |
| 2021-12-31 | Mr. Shelton | $5.13M | $9.64M | $1.92M | $3.12M | $359.48 | $190.28 | $275.53M | $19.35M | 2023-03-31 |
| 2020-12-31 | Mr. Shelton | $5.48M | $15.79M | $1.81M | $4.50M | $266.59 | $135.64 | $32.69M | -$670.00K | 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |